$NTLA

Intellia Therapeutics Inc

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$59.5 β–Ό-0.101%

Extented Hours

VOLUME

852,193

DAY RANGE

59.05 - 62.82

52 WEEK

37.08 - 180.59

Join Discuss about NTLA with like-minded investors

profile
@dros #droscrew
recently

RECAP 7/18 Unusual Puts: $TTWO Sep 125 P $WDAY Jul29 125 P $BHC Aug 5 P $DKNG Oct 10 P $QS Jul29 10.5/8.5 P Spd $BBBY Jan-24 2 P $PTON Jan-24 5 P $OXY Jun 30 P $NTLA Aug 40 P $SGEN Aug 150 P

125 Replies 7 πŸ‘ 10 πŸ”₯

profile
@dros #droscrew
recently

+Initiations 1/7: $ACVA $AER $BILL $CMPO $CSTL $DMTK $DNA $ET $GDRX $IMRX $NRDY $NTLA $OCX $PL $PSTX $RBOT $SSNC $UPWK $VCYT

100 Replies 7 πŸ‘ 8 πŸ”₯

FA
@FabioT #decarolis
recently

poi NTLA ... area 90

62 Replies 7 πŸ‘ 12 πŸ”₯

profile
@Marcosx #ivtrades
recently

$NTLA Nutella ? lol

72 Replies 13 πŸ‘ 13 πŸ”₯

profile
@CarlosH-carvan #ivtrades
recently

Cathie Wood's ARK Invest Posts Fund Purchases For Monday, Nov. 1, 2021: NTLA, BEAM, PATH, KTOS, VLD, NIU, BLDE, MKFG, ZM, GENI, EXAS, CDNA, ALLO, VERV, ARCT, ADPT, TWLO, HOOD, TOST

122 Replies 10 πŸ‘ 15 πŸ”₯

profile
@dros #droscrew
recently

+Initiations 9/24: $ACHC $AMBP $AVTX $CLBT $CYCN $EHC $FNV $FYBR $HTHT $HUMA $LEV $NTLA $OPEN $OSMT $PAYO $RPD $SMFR $WPM . -Initiations 9/24: $AMED $SPOT $UHS

142 Replies 15 πŸ‘ 13 πŸ”₯

profile
@marketjay #Market Assassin Corp
recently

I've had 5 high conviction trades the past 2 months, meaning on my scale of 1 to 5 trade set ups that met 5 stars. SAVA, DXCM, SWBI, NTLA, & MP SAVA netted me a 600% return, DXCM 450%, SWBI 500%, NTLA I didn't trade because of confusion of dates, and MP just didn't work. So I'm 3/5 for those, and these have allowed each account to sit comfortably

51 Replies 15 πŸ‘ 6 πŸ”₯

DO
@Donnieasoff #Market Assassin Corp
recently

I have some long term holds I won't be giving up like ntla, UPST, FCX a lot of shit which could get hit but I love been long since such low levels I'm chillin

59 Replies 12 πŸ‘ 12 πŸ”₯

profile
@marketjay #Market Assassin Corp
recently

planned for NTLA in June when the data trials were being released and botched the play by being unaware of the date tge weej prior before price jumped from $83 to $160

66 Replies 7 πŸ‘ 7 πŸ”₯

DO
@Donnieasoff #Market Assassin Corp
recently

ntla is such a winner I went long stock I February and doubled In March such a winner. lol only regret isn't using leverage

121 Replies 11 πŸ‘ 13 πŸ”₯

profile
@marketjay #Market Assassin Corp
recently

I have a extensive watchlist based on data and key dates, previous plays from that list are NTLA, SAVA

126 Replies 10 πŸ‘ 10 πŸ”₯

profile
@marketjay #Market Assassin Corp
recently

NTLA is creating a W pattern on the daily, watch for the break above $170 for continuation of strength with a PT: $190 with two weeks minimum out

90 Replies 6 πŸ‘ 12 πŸ”₯

profile
@ivtrades-Chris #ivtrades
recently

$NTLA dancing

109 Replies 15 πŸ‘ 8 πŸ”₯

profile
@DarkPoolAlgo #Dark Pool Charts
recently

Thursday, August 5, 2021 Futures Up/Down % Last Dow 55.00 0.16% 34,745 S&P 500 9.25 0.22% 4,404 Nasdaq 33.50 0.22% 15,107 U.S. futures are looking up modestly, rising roughly about 0.2% across the board into one of the heaviest days of corporate earnings of the season, as major averages continue to hold not far off record highs. The S&P 500 index has held the pivotal 4,400 level for over a week now, as overall major averages have moved sideways for two or three weeks now, bolstered by rising on better economic data, earnings results, and an accommodative Fed, which has offset rising Delta variant concerns and fears of further global restrictions to contain the rise in cases and tighter government restrictions in China. Oil prices edge higher after sliding sharply the last 3-days on demand concerns. Bitcoin prices are down about 4% holding just above the $38,000 level while Ethereum slips nearly 4% to 2,600 in the crypto sector. Ahead of tomorrow’s nonfarm payrolls report, investors will get two more labor market data points with the Challenger jobs report at 7:30 and the weekly jobless claims. Euro Stoxx 50 rises 0.5% around best levels for the week. Wednesday’s after-hours big-name earnings were disappointing for the most part, which could weigh on sentiment. Major averages ended the session mixed on Wednesday, following conflicting signals on the economy that showed a hot services sector, but a labor market that continues to struggle to find workers. The Institute for Supply Management survey on Wednesday jumped to a record high of 64.1 in July, but the ADP Employment Report showed private payrolls only rose by 330,000 last month, well shy of the 695,000 estimate ahead of tomorrow’s payrolls. The Dow Jones saw the biggest fall, dragged lower by a decline of more than 6% in Amgen in the wake of its quarterly results, accounting for about 103 points to the downside while energy was the weakest sector on the day, suffering its biggest daily percentage drop since July 19. In Asian markets, The Nikkei Index gained 144 points to 27,728, the Shanghai Index dipped -10 points to 3,466 and the Hang Seng Index declined -221 points (0.84%) to settle at 26,204. In Europe, markets are little changed as the German DAX is up a few points at the 15,700 level, while the FTSE 100 is down a couple of points at 7.120. Market Closing Prices Yesterday The S&P 500 Index slipped -20.49 points, or 0.46%, to 4,402.66 The Dow Jones Industrial Average fell -323.73 points, or 0.92%, to 34,792.67 The Nasdaq Composite edged higher 19.24 points, or 0.13%, to 14,780.53 The Russell 2000 Index declined -27.26 points, or 1.23% to 2,196.32 Events Calendar for Today 7:30 AM ET Challenger Job Layoffs for July 8:30 AM ET Weekly Jobless Claims 8:30 AM EST Continuing Claims 10:30 AM ET Weekly EIA Natural Gas Inventory Data Earnings Calendar: Earnings Before the Open: ABMD, ADNT, AES, AHCO, AKBA, AMRS, ARWR, AVEO, BBGI, BCRX, BDX, BERY, BKI, BLDR, BLL, BV, CAH, CARS, CCOI, CHH, CI, CNP, COMM, CRAI, DDOG, DIN, DLX, DUK, ECOM, EPAM, EPC, EVRG, FOUR, GCP, GNL, GOGO, GOLF, GTN, HBI, HBIO, HII, HL, IDCC, INSM, IRM, IRWD, ITI, K, KPTI, LAMR, LAUR, LNG, LXP, MMS, MPLN, MRNA, MUR, MYE, NINE, NS, NTLA, PCTY, PBH, PBPB, PEI, PENN, PH, PNW, PPL, PRTY, PWR, PZZA, RC, RDUS, REGN, ROLL, SEAS, SSYS, TEN, THS, TRGP, UFS, USPH, VG, VIAC, VST, W, WD, WOW, WRK, XEC, XERS, XTNT, XXII, YETI, ZIXI, ZTS Earnings After the Close: AAOI, AEE, AEL, AIG, AINV, ALRM, ALTR, AMBC, APLE, APPN, ARNA, ASTG, AVLR, AXON, BAND, BECN, BGS, BHF, BIGC, BKD, BL, BRBR, BRKS, BYND, CARG, CDXS, CGNX, CHRS, CHUY, CLNE, CNXN, COLD, CSOD, CVNA, CWK, DBX, DHX, DIOD, EB, ECOR, EGLE, ENTA, ENV, ERII, EXEL, EXPE, FEYE, FLDM, FLS, FND, FOXF, FSR, FTSI, G, GDYN, GEOS, GH, GKOS, GPRO, GRPN, GSBD, HASI, HCAT, HCI, HEAR, HTA, IFF, ILMN, IHRT, IOVA, IRTC, ITT, JCOM, KALA, KAMN, LGF.A, LNT, LOCO, LTHM, MAIN, MDRX, MNST, MP, MSI, MTW, MTZ, NET, NKTR, NVAX, NWSA, NYMT, OLED, OUT, PBYI, PK, PODD, POST, PRA, QDEL, RAMP, RDFN, REZI, RMD, RUN, SFM, SGMO, SHAK, SPCE, SQ, SYNA, TDC, TGH, TMDX, TMST, TRUE, TRUP, TTOO, VLDR, VMEO, VOYA, VV, WSC, Y, YELP, ZEUS, ZG, ZNGA Macro Up/Down Last Nymex 0.37 68.52 Brent 0.26 70.64 Gold 0.40 1,811.75 EUR/USD 0.0005 1.1842 JPY/USD 0.03 109.51 10-Year Note -0.004 1.19% Sector News Breakdown Consumer Boot Barn ($BOOT) Q1 EPS $1.35 vs est. $0.88 in revs $306.3M vs est. $288.9M; same-store sales +78.9% vs 1Q20, +52.3% vs 1Q19; opened 3 new stores in the quarter Costco ($COST) reported total comparable sales for July of +13.8%; July U.S. comparable sales excluding fuel, currencies +8.5% L.F. Beauty ($ELF) 1Q EPS $0.15 vs est. $0.15 on sales $97Mm vs est. $79.3Mm; guides FY adj EPS $0.65-0.68 vs est. $0.67, sees FY sales $356-364Mm vs est. $350.5Mm Etsy Inc. ($ETSY) shares tumble -13% on guidance; 2Q EPS $0.68 vs est. $0.63 on revs $528.9Mm vs est. $524.7Mm, qtrly consolidated GMS $3.0B +13%; guides 3Q revs $500-525Mm vs est. $524.7Mm, sees 3Q GMS $2.9-3.0B Frontdoor Inc. ($FTDR) Q2 EPS $0.76 vs est. $0.63 on revs $462M vs est. $466M, sees Q3 revenue $470M-$480M, lowered FY revenue outlook to $1.6B-$1.62B (est. $1.64B) from $1.63B-$1.65B Jack in the Box ($JACK) Q3 EPS $1.79 vs est. $1.49 on revs $269.5M vs est. $258.5M, same-store sales +10.2%, systemwide sales +10.6%, company-operated same-store sales +9.0%, sees FY21 capex $40M-$45M, FY22 capex $65M-$75M Leslie’s ($LESL) Q3 adj EPS $0.64 vs. est. $0.55; Q3 revs $596.54M vs. est. $570.37M; Q3 comparable sales growth of 23.9%; raises FY21 adjusted EPS view 80c-85c from 75c-80c (est. 77c) and boosts FY21 revs to $1.31B-$1.33B from $1.28B-$1.3B (est. $1.3B); Adjusted EBITDA of $179.3 million compared to $119.8 million in the prior year quarter, an increase of 49.7% MGM Resorts ($MGM) 2Q adj EPS ($0.13) vs est. ($0.30) on net revs $2.3B vs est. $2.28B, MGM China net revs $311Mm, LV Strip net revs $1.0B, regional net revs $856Mm Rent-A-Center ($RCII) 2Q adj EPS $1.63 vs est. $1.35 on revs $1.2B vs est. $1.14B, qtrly comps +16.6% led by e-comm; guides FY revs $4.55-4.67B vs est. $4.56B, sees Rent-A-Center segment revs $2.02-2.06B, sees FY adj EPS $5.90-6.40 vs est. $5.66; announces $250Mm repurchase auth Uber ($UBER) Q2 EPS $0.58 on revs $3.93B vs. est. $3.74B; Q2 gross bookings grew 114% yoy to $21.9 billion, or 104% on a constant currency basis, with Mobility Gross Bookings of $8.6 billion and Delivery Gross Bookings of $12.9 billion; Q2 Adj EBITDA Loss $509M vs. est. loss $324.5M; sees Q3 Adj EBITDA loss below $100M vs. est. loss $95.4M Wynn Resorts (WYNN) 2Q adj EPS ($1.12) vs est. ($1.61) on revs $990.1Mm vs est. $932.5Mm, Wynn Macau revs $184Mm, LV ops revs $355.1Mm ADT Inc. ($ADT) adj EPS ($0.07) vs est. $0.25 on revs $1.304B vs est. $1.28B; Gross recurring monthly revenue (RMR) additions grew 28%; end of period RMR of $352 million increased by 4%; solid customer retention with attrition at 13.3% Driven Brands ($DRVN) 12M share Secondary priced at $29.50 European Wax Center ($EWCZ)6M share IPO priced at $17.00 Weber ($WEBR) 18M (which was cut down from 46.8M) share IPO priced at $14.00 Energy APA Inc. ($APA) Q2 adj EPS $0.70 vs. est. $0.57’ Q2 revs $1.75B vs. est. $1.46B; qtrly adjusted production, which excludes Egypt noncontrolling interest and tax barrels, was 342,000 boe per day; at current strip prices, we expect to generate approximately $1.7B of free cash flow this year Earthstone Energy ($ESTE) files for offering of up to 6.2 mln shares of class a common stock by selling stockholders Marathon Oil ($MRO) Q2 EPS $0.22 vs. est. $0.15; Q2 revs $1.14B vs. est. $1.09B; Q2 oil-equivalent production of 348,000 net boed; raising 2021 full year oil-equivalent production guidance by 5,000 net boed; Q2 oil production of 170,000 net bopd; raised quarterly base dividend by 25% to 5c; raising the midpoint of its 2021 full year U.S. oil-equivalent production guidance by 5,000 net boed Warrior Met Coal ($HCC) 2Q adj EPS $0.25 vs est. ($0.18) on revs $227.4Mm vs est. $128.3Mm; not providing FY guide at this time Whiting Petroleum ($WLL) Q2 adj EPS $3.01 vs. est. $1.97; Q2 revs $352M vs. est. $244.27M; said generated net cash provided by operating activities of $183M and $111M in adjusted free cash flow during the quarter and over $200 million through six months; raises FY21 production view to 88-92 MBOE per day from 82-88 Financials Allstate Corp. ($ALL) Q2 adj EPS $3.79 vs. est. $3.04; Q2 revs $12.65B vs. est. $10.51B; announces new $5B repurchase program; 2Q Book Value Per Shr $86.33; Q2 Catastrophe Loss $952M; Q2 Property-Liability Premiums Earned $10.01B; 2Q Property-Liability Premiums Written $10.32B;2Q Property-Liability Combined Ratio 95.7 Fleetcor ($FLT) Q2 EPS $2.30 vs est. $2.94, adj EPS $3.15, on revs $667.4M vs est. $637.3M; its board increased its share repurchase authorization by$1B; sees Q3 adj EPS $3.35-$3.55 vs est. $3.36, and raised outlook for FY adj EPS to $12.80-$13 (est. $12.61) from $12.32-$12.88 and FY revs to $2.74B-$2.79B (est. $2.68B) from $2.6B-$2.7B Lemonade ($LMND) Q2 EPS loss (-$0.90) vs. est. loss (-$0.89); Q2 revs $28.2M vs. est. $26.8M; customer count increased by 48% to 1,206,172 yoy; premium per customer, defined as in force premium divided by customers, was $246 at the end of the second quarter, up 29% yoy; raises FY21 revenue view to $123M-$125M from $117M-$120M (est. $118.94M); narrows FY21 adjusted EBITDA view to ($173M)-($169M) from ($173M)-($163M) Lincoln National ($LNC) Q2 adj operating EPS $3.17 vs. est. $2.35; Q2 revs $4.85B vs. est. $4.72B; Reports book value per share, including AOCI, of $115.00, up 7%; BVPS, excluding AOCI, of $75.45, up 9% MetLife ($MET) announces new $3B share repurchase authorization; Q2 adj EPS $2.37 vs. est. $1.57; Q2 revs $18.52M vs. est. $15.77B; qtrly premiums, fees & other revenues $11.22 bln vs $10.49 bln; qtrly net investment income $5.28 bln vs $4.09 bln; book value of $75.86 per share at qtr-end, down 4% from $78.65 per share at June 30, 2020 RE/MAX Holdings ($RMAX) 2Q adj EPS $0.63 vs est. $1.31 on revs $77.2Mm vs est. $76.4Mm; guides 3Q revs $86.5-91.5Mm vs est. $79.1Mm; sees FY revs $321-336Mm vs est. $308.7Mm Western Union (WU) Q2 adj EPS $0.48 vs. est. $0.47; Q2 revs $1.3B vs. est. $1.26B; reaffirms FY21 adj EPS view $2.00-$2.10 vs. est. $2.06; reaffirms FY21 revenue growth view mid-to-high single digits; Consumer-to-Consumer (C2C) transactions increased 15% in the quarter, while revenues increased 15% on a reported basis, or 12% constant currency. Robinhood ($HOOD) filed with the SEC a prospectus related to the offer and sale from time to time of up to 97,876,033 shares of Class A common stock of Robinhood Markets, Inc. by certain selling stockholders

129 Replies 15 πŸ‘ 14 πŸ”₯

profile
@marketjay #Market Assassin Corp
recently

to be real deep down im still whining to myself how did i botch NTLA

69 Replies 14 πŸ‘ 7 πŸ”₯

profile
@dros #droscrew
recently

$NTLA ceo on CNBCΒ 

148 Replies 7 πŸ‘ 8 πŸ”₯

profile
@marketjay #Market Assassin Corp
recently

damn dropped the ball on those NTLA 90 calls, completely missed timed it

66 Replies 11 πŸ‘ 9 πŸ”₯

profile
@Navneet #droscrew
recently

$ntla 155 calls flow yesterday came 2.50

59 Replies 7 πŸ‘ 13 πŸ”₯

profile
@marketjay #Market Assassin Corp
recently

SWBI 25 call signaled .47 ran as high as 10.70 today with another 2 week's to go, ASTS 12.50 call alerted at 1.82 ran as high as 5.00 today, QSI 10 call alerted at .95 ran as high as 3.80, all of these don't expire until 07/16. That is only this months top plays, without including the NTLA blunder, we still got the 2nd half of this year guys so EVERYBODY KEEP GRINDING

143 Replies 10 πŸ‘ 15 πŸ”₯

profile
@marketjay #Market Assassin Corp
recently

everyone here and in the Capatalist Academy should've caught NTLA as it was on our watchlist and we had a discussion call about it and i lost track of the date

113 Replies 9 πŸ‘ 9 πŸ”₯

profile
@marketjay #Market Assassin Corp
recently

Previous moves from off the extended watchlist that made it to the weekly watchlist ETSY 06/21 went $169 to $202, NTLA 06/13 on the watchlist and alerted that phase 1 data was to be released, went from $85 to currently $151, NOW 06/18 went from $510 to now $558. Some plays on the weekly watchlist come from my extended watchlist unfortunately I'm human I will miss my own plays sometimes as I waited for NTLA and missed time it by a week. So use the watchlist as a screener @everyone

84 Replies 11 πŸ‘ 7 πŸ”₯

profile
@marketjay #Market Assassin Corp
recently

NTLA shares trading higher today due to positive trial data this is positive and provides future clarity on CRSP technology

134 Replies 13 πŸ‘ 12 πŸ”₯

profile
@dros #droscrew
recently

yeah in sympathy with ntlaΒ 

55 Replies 9 πŸ‘ 9 πŸ”₯

profile
@dros #droscrew
recently

$NTLA lit on drug trial resultsΒ 

51 Replies 13 πŸ‘ 14 πŸ”₯

profile
@CarlosH-carvan #ivtrades
recently

$NTLA to $110/$163

104 Replies 7 πŸ‘ 7 πŸ”₯

profile
@marketjay #Market Assassin Corp
recently

NTLA with a strong recovery

78 Replies 10 πŸ‘ 8 πŸ”₯

profile
@marketjay #Market Assassin Corp
recently

NTLA tanked

98 Replies 9 πŸ‘ 13 πŸ”₯

profile
@marketjay #Market Assassin Corp
recently

NTLA slightly green but sideways without the conviction and follow through

79 Replies 12 πŸ‘ 12 πŸ”₯

profile
@marketjay #Market Assassin Corp
recently

DXCM NTLA favorable momentum

103 Replies 15 πŸ‘ 14 πŸ”₯

profile
@marketjay #Market Assassin Corp
recently

NTLA creeping

131 Replies 9 πŸ‘ 9 πŸ”₯

profile
@marketjay #Market Assassin Corp
recently

Currently NOW is a voided trade off the watchlist as it played out the way we wanted yesterday, MSTR already achived, ATVI and REGN have not met criteria yet, HON, NTLA, and DXCM all active, ADBE moving strongly but I will be waiting for earnings

71 Replies 11 πŸ‘ 7 πŸ”₯

profile
@marketjay #Market Assassin Corp
recently

NTLA pre market got as high as $89.32, still holding our $90 call

115 Replies 10 πŸ‘ 12 πŸ”₯

profile
@marketjay #Market Assassin Corp
recently

NTLA and HON light swings

82 Replies 15 πŸ‘ 10 πŸ”₯

profile
@marketjay #Market Assassin Corp
recently

And swing trade DXCM, NTLA, and HON

73 Replies 8 πŸ‘ 9 πŸ”₯

profile
@marketjay #Market Assassin Corp
recently

Volume is stepping into NTLA, want to see higher volume as this is gaining momentum

92 Replies 6 πŸ‘ 14 πŸ”₯

profile
@marketjay #Market Assassin Corp
recently

NTLA confirmed but no liquidity is no good

55 Replies 11 πŸ‘ 14 πŸ”₯

profile
@marketjay #Market Assassin Corp
recently

watching NTLA A+ set up on the play but there is no volume on the 90 calls for June or July which sucks may just buy shares because they are a great company for anyone interested in genomics they're my number 2 genomic company after CRSP

138 Replies 14 πŸ‘ 8 πŸ”₯

Key Metrics

Market Cap

4.88 B

Beta

2.35

Avg. Volume

1.20 M

Shares Outstanding

76.01 M

Yield

0%

Public Float

0

Next Earnings Date

2022-11-03

Next Dividend Date

Company Information

Intellia Therapeutics is a leading clinical-stage genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creating enhanced engineered cells that can treat oncological and immunological diseases. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create new classes of therapeutic products.

CEO: John Leonard

Website:

HQ: 40 Erie St Ste 130 Cambridge, 02139-4254 Massachusetts

Related News